Colonics
About Me
Recent Posts
- Improved Access To Care For Young Adults Allowed To Stay On Parents' Health Insurance
- New Approach Means Tissue Engineering May Be Possible In Any Lab
- Physical Activity Yields Feelings Of Excitement, Enthusiasm
- How Stimulants Work To Control Hyperactivity
- Newborn Lives Can Be Saved By Cleansing The Umbilical Cord With Chlorhexidine
Menu
Calendar
| Mon | Tue | Wed | Thu | Fri | Sat | Sun |
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | ||
| 6 | 7 | 8 | 9 | 10 | 11 | 12 |
| 13 | 14 | 15 | 16 | 17 | 18 | 19 |
| 20 | 21 | 22 | 23 | 24 | 25 | 26 |
| 27 | 28 | 29 | ||||
Friends
Links
Entry 1 of 2282
Last Page | Next Page
3/16/2010
-
Vertex Pharmaceuticals' telaprevir and VX-222 HCV inhibitor abstracts accepted for presentation at 45th EASL meeting
|
Vertex Pharmaceuticals Incorporated today announced that several abstracts related to the hepatitis C virus (HCV) protease inhibitor telaprevir and the HCV polymerase inhibitor VX-222 were accepted for launch at the 45th Annual Meeting of the latin band for the Study of the Liver (EASL) in Vienna, Austria, April 14-18, 2010. More: - Read the rest here |
Post A Comment! :: Send to a Friend! |
Share and enjoy
